BDS-1
Kurzübersicht für BDS-1 (ABIN2566174)
Applikation
-
-
Verwendungszweck
- BDS-I is a selective blocker of Kv3.4 channel
-
Sequenz
- AA sequence: Ala-Ala-Pro-Cys4-Phe-Cys6-Ser-Gly-Lys-Pro -Gly-Arg-Gly-Asp-Leu-Trp-Ile-Leu-Arg-Gly- Thr-Cys22-Pro-Gly-Gly-Tyr-Gly-Tyr-Thr-Ser- Asn-Cys32-Tyr-Lys-Trp-Pro-Asn-Ile-Cys39->Cys40 -Tyr-Pro-His-OH br>Disulfide bonds: Cys4-Cys39, Cys6-Cys32, Cys22-Cys40
-
Produktmerkmale
- BDS-1 is a 43 amino acid peptide which was originally isolated from the venom of the sea anemona Anemonia Viridis. BDS-1 was originally described as a highly selective blocker of the rapidly inactivating voltage-gated potassium channel Kv3.4/ KCNC4, a potential therapeutic target for major CNS disorders (Alzheimer and Parkinson diseases). The toxin acts as gating modifiers, mainly by shifting the voltage-dependence of activation. Channel block occurs with high affinity (IC50 of 43 nM) and is rapid and reversible. BDS-1 also blocks the Kv3.1 and Kv3.2 channels albeit with a lower affinity (>200 nM). Finally, in a more recent study, it was demonstrated that BDS-1 is a selective gating activator of the Nav1.7 channel subtype, an important target for pain management. On the human isoform, modulation is witnessed by a drastic slowing of channel inactivation which occurs with an IC50 of 3 nM.
-
Formel
- C210H297N57O56S6
-
-
-
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Solid
-
Lagerung
- -20 °C
-
-
-
Molekulargewicht
- 4708.37 Da
-
-